Abstract #4092
Effect of cabozantinib on K trans and v e values in castration-resistant prostate cancer
Milica Medved 1 , Aytekin Oto 1 , Xiaobing Fan 1 , Federico D Pineda 1 , Gregory S Karczmar 1 , and Russell Z Szmulewitz 2
1
Radiology, University of Chicago, Chicago,
Illinois, United States,
2
Medicine,
University of Chicago, Chicago, Illinois, United States
Cabozantinib shows promising results in extension of
progression-free survival for men with
castration-resistant prostate cancer. In this
preliminary report, we document the effect of
cabozantinib on perfusion in bone metastases in
castration-resistant prostate cancer and in muscle
tissue using the Tofts model parameters K
trans
and
v
e
. We find a statistically significant
decrease in lesion K
trans
(37%
on average, p < 0.01) during the first two weeks of
therapy, while other quantities were not significantly
changed. It remains to be seen whether individual
changes in lesion K
trans
can
be correlated with treatment response.
How to access this content:
For one year after publication, abstracts and videos are only open to registrants of this annual meeting. Registrants should use their existing login information. Non-registrant access can be purchased via the ISMRM E-Library.
After one year, current ISMRM & ISMRT members get free access to both the abstracts and videos. Non-members and non-registrants must purchase access via the ISMRM E-Library.
After two years, the meeting proceedings (abstracts) are opened to the public and require no login information. Videos remain behind password for access by members, registrants and E-Library customers.
Click here for more information on becoming a member.
